The global dilated cardiomyopathy therapeutics market is studied in this report from three perspectives: by drug class, by pipelined products and by geography. Dilated cardiomyopathy therapeutics market by drug class encompasses aldosterone antagonists, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) and beta-blockers. A detailed market analysis and forecast for each of these segments have been provided in this study, in terms of market revenue (USD million) for the period 2016 to 2026. The report also provides the compounded annual growth rate (CAGR %) for each of these segments for the forecast period from 2019 to 2026, considering 2016 and 2018 as base years. Geographic regions analyzed for this market include North America, Europe, Asia Pacific and Rest of the World. The North American market comprises the United States and Canada. The European market includes countries such as the U.K., Germany, Italy, and Spain that majorly contribute towards the growth of this region. Similarly, the Asia Pacific market primarily considers India, China, Japan, Singapore, and Australia, along with other smaller markets.
The market overview section of the report demonstrates the major factors determining the market dynamics such as drivers, restraints and opportunities that influence the current as well as future status of this industry. The market overview section of the report also includes qualitative and quantitative analysis of the competitive landscape covering market share analysis by key players.
The study also suggests a list of recommendations which would be useful for existing and future market players in decision making for business growth. Pipeline analysis (Phase I and Phase II) for dilated cardiomyopathy therapeutics market has also been covered in the report. The report concludes with the company profiles section, which illustrates key information about the major players in this market such as company overview, financial overview, product portfolio, business strategies and recent developments. Key players profiled in the report include Array BioPharma, Inc., AstraZeneca plc, Celladon Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd, and Vericel Corporation.
Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.3.1 Secondary Research
1.3.2 Primary Research
1.4 List of Abbreviations
1.5 Assumptions and Stipulations
Chapter 2 Executive Summary
2.1 Market Snapshot: Global Dilated Cardiomyopathy Therapeutics Market (2018 & 2026)
2.2 Comparative Analysis: Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Geography, 2018 & 2026 (Value %)
Chapter 3 Global Dilated Cardiomyopathy Therapeutics Market Overview
3.1 Market Definition and Overview
3.1.1 Classification of Cardiomyopathies
3.1.2 Market Drivers
3.1.2.1 Increasing number of heart failure cases worldwide will lead to rise in demand for effective medications, thereby driving market growth
3.1.3 Market Restraints
3.1.3.1 Side effects associated with DCM drugs could restrain market growth
3.1.3.2 Enhanced relief from use of devices without any side effects will restrain the dilated cardiomyopathy drugs market
3.1.4 Promising gene and stem cell therapies for DCM treatment may hamper the DCM drugs market growth
3.1.5 Market Opportunities
3.1.7 Increasing genericization of DCM drugs
3.2 Market Attractiveness Analysis: Global Dilated Cardiomyopathy Therapeutics Market, by Geography, 2018
3.3 Epidemiology (Prevalence, Cause, Mortality Rate)
3.4 Epidemiology Studies on Dilated Cardiomyopathy
3.5 Causes and Mortality
3.6 Event Impact Analysis
3.7 Competitive Landscape, by Key Players, 2018 (Value %)
3.7.1 Market share by key players, 2018 (Value %)
Chapter 4 Global Dilated Cardiomyopathy Therapeutics Market, by Drug Class
4.1 Introduction
4.1.1 Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Drug Class 2016 – 2026 (USD Million)
4.2 Aldosterone Antagonists
4.2.1 Global Aldosterone Antagonists Market Revenue, 2016 - 2026 (USD Million)
4.3 Angiotensin-Converting Enzymes (ACE) Inhibitors
4.3.1 Global Angiotensin-Converting Enzyme (ACE) Inhibitors Market Revenue, 2016 - 2026 (USD Million)
4.4 Angiotensin II Receptor Blocker (ARBs)
4.4.1 Global Angiotensin II Receptor Blockers (ARBs) Market Revenue, 2016 - 2026 (USD Million)
4.5 Beta-Blockers
4.5.1 Global Beta-Blockers Market Revenue, 2016 - 2026 (USD Million)
Chapter 5 Pipeline Analysis of Global Dilated Cardiomyopathy Therapeutics Market
5.1 Pipeline Analysis
5.1.1 Pipeline Analysis : Dilated Cardiomyopathy Therapeutics Market
Chapter 6 Global Dilated Cardiomyopathy Therapeutics Market, by Geography
6.1 Introduction
6.1.1 Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Geography, 2016 - 2026 (USD Million)
6.2 North America
6.2.1 North America Dilated Cardiomyopathy Therapeutics Market Revenue, 2016 - 2026 (USD Million)
6.3 Europe
6.3.1 Europe Dilated Cardiomyopathy Therapeutics Market Revenue, 2016 - 2026 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Dilated Cardiomyopathy Therapeutics market Revenue, 2016 - 2026 (USD Million)
6.5 Rest of the World (RoW)
6.5.1 Rest of the World Dilated Cardiomyopathy Therapeutics Market Revenue, 2016 - 2026 (USD Million)
Chapter 7 Recommendations
7.1 Dilated phase of hypertrophic cardiomyopathy
7.2 Genetic Intervention
Chapter 8 Company Profiles
8.1 Array BioPharma, Inc.
8.1.1 Company Overview
8.1.2 Financial Overview
8.1.3 Product Portfolio
8.1.4 Business Strategies
8.1.5 Recent Developments
8.2 AstraZeneca plc
8.2.1 Company Overview
8.2.2 Financial Overview
8.2.3 Product Portfolio
8.2.4 Business Strategies
8.2.5 Recent Developments
8.3 Celladon Corporation
8.3.1 Company Overview
8.3.2 Financial Overview
8.3.3 Product Portfolio
8.3.4 Business Strategies
8.3.5 Recent Developments
8.4 GlaxoSmithKline plc
8.4.1 Company Overview
8.4.2 Financial Overview
8.4.3 Product Portfolio
8.4.4 Business Strategies
8.4.5 Recent Developments
8.5 Janssen Pharmaceuticals, Inc.
8.5.1 Company Overview
8.5.2 Financial Overview
8.5.3 Product Portfolio
8.5.4 Business Strategies
8.5.5 Recent Developments
8.6 Merck & Co., Inc.
8.6.1 Company Overview
8.6.2 Financial Overview
8.6.3 Product Portfolio
8.6.4 Business Strategies
8.6.5 Recent Developments
8.7 Novartis International AG
8.7.1 Company Overview
8.7.2 Financial Overview
8.7.3 Product Portfolio
8.7.4 Business Strategies
8.7.5 Recent Developments
8.8 Pfizer, Inc.
8.8.1 Company Overview
8.8.2 Financial Overview
8.8.3 Product Portfolio
8.8.4 Business Strategies
8.8.5 Recent Developments
8.9 Sanofi S.A.
8.9.1 Company Overview
8.9.2 Financial Overview
8.9.3 Product Portfolio
8.9.4 Business Strategies
8.9.5 Recent Developments
8.10 Teva Pharmaceutical Industries Ltd.
8.10.1 Company Overview
8.10.2 Financial Overview
8.10.3 Product Portfolio
8.10.4 Business Strategies
8.10.5 Recent Developments
8.11 Vericel Corporation
8.11.1 Company Overview
8.11.2 Financial Overview
8.11.3 Product Portfolio
8.11.4 Business Strategies
8.11.5 Recent Developments
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers